NCT03248856

Brief Summary

In this study Triamcinolone acetonide will be applied intratympanically before cochlear implant surgery. After round window exposure, a perilymph sample and simultaneously a blood sample will be drawn. Triamcinolone levels will then be analyzed in the samples.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Oct 2017

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 14, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

October 2, 2017

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2021

Completed
Last Updated

September 28, 2021

Status Verified

September 1, 2021

Enrollment Period

3.2 years

First QC Date

August 9, 2017

Last Update Submit

September 25, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Triamcinolone levels in comparison

    Absorption of Triamcinolone acetonide in cochlear perilymph in comparison to dissemination to the blood circulation

    2 years

Secondary Outcomes (3)

  • Triamcinolone stability

    2 years

  • Triamcinolone concentrations

    2 years

  • Impedances

    2 years

Study Arms (4)

Group 1

OTHER

Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.

Drug: Triamcinolone Acetonide

Group 2

OTHER

Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.

Drug: Triamcinolone Acetonide

Group 3

OTHER

Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.

Drug: Triamcinolone Acetonide

Group 4

OTHER

Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.

Drug: Triamcinolone Acetonide

Interventions

Intratympanic administration

Group 1Group 2Group 3Group 4

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients between 18 and 90 years will be included in the study, who will undergo a cochlear implantation and are willing to participate in the study

You may not qualify if:

  • Patients younger than 18 years
  • Patients who receive cortisone on a regular basis or receive cortisone i.v. or p.o. preoperatively
  • Patients with contraindications against the administration of Volon A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna (AKH)

Vienna, 1090, Austria

Location

Related Publications (1)

  • Dahm V, Gausterer JC, Auinger AB, Honeder C, Gabor F, Reznicek G, Kaider A, Riss D, Arnoldner C. Evaluation of Levels of Triamcinolone Acetonide in Human Perilymph and Plasma After Intratympanic Application in Patients Receiving Cochlear Implants: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Nov 1;147(11):974-980. doi: 10.1001/jamaoto.2021.2492.

MeSH Terms

Conditions

Hearing Loss, Sensorineural

Interventions

Triamcinolone Acetonide

Condition Hierarchy (Ancestors)

Hearing LossHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TriamcinolonePregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assoc Prof PD Dr.

Study Record Dates

First Submitted

August 9, 2017

First Posted

August 14, 2017

Study Start

October 2, 2017

Primary Completion

December 31, 2020

Study Completion

May 31, 2021

Last Updated

September 28, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL
Time Frame
January 2020

Locations